Japanese T2DM patients aged 20-74 years with hemoglobin A1c ( HbA1c ) of 6.9-10 .5 % , fasting plasma glucose ( FPG ) 126mg/dL and on diet therapy were randomized in a double-blind manner to receive luseogliflozin ( 0.5 , 2.5 , or 5mg ) or placebo once daily for 12 weeks ( n = 61 , 61 , 61 , and 56 , respectively ) .